Unlike the use of PI3K inhibitors in solid tumor malignancies, the anti-tumor effects of PI3K inhibition in lymphoid malignancies are not dependent on gene mutations, amplifications, or deletions within the PI3K pathway. This evidence concerns the gene PIK3CA and neoplasm.